Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study
Disease control
Not yet recruiting
This study looks at how well a drug called glofitamab (a bispecific antibody) works for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are observing about 200 adults in China who are already…
Sponsor: Yanyan Liu • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC